source
- RallyBio tries again for reverse merger, this time with AvenzoIt's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.BioPharma Dive · 1mo ago↗ source
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.BioPharma Dive · 1mo ago↗ source
- As FDA misses deadline on electric shock ban, disability advocates speak outThe FDA has missed a self-imposed deadline to ban the use of electrical shock devices in people with intellectual disabilities.STAT